| Volume: | 7,320,745 |
|---|---|
| Day's Low: | $36.00 |
| 52-wk Low: | $27.21 |
| Previous Close: | $36.12 |
| Dividend: | $0.49 |
| Market Cap: | 42,042,700 |
| Avg Volume: | 6,809,000 |
|---|---|
| Day's High: | $36.70 |
| 52-wk High: | $40.78 |
| Open Price: | $36.04 |
| Yield: | 5.36% |
| P/E (Forward): | 8.28 |
| 9:12 PM | 11/19/2009 | CORRECT:Justice Dept's Health-Care Fraud Caseload Nears 1,000 |
| 10:03 AM | 11/19/2009 | Eli Lilly To Pay $2 Million Cash Severance To Retiring R&D Chief |
| 8:04 PM | 11/16/2009 | UPDATE: Icahn Reports New Stakes In Genzyme, Forest Labs |
| 8:15 AM | 11/15/2009 | Proposed AstraZeneca Anticlotting Drug Better Than Plavix:Study |
| 9:48 AM | 11/13/2009 | AstraZeneca Research Chief Lundberg To Join Eli Lilly |
| 12:47 PM | 11/12/2009 | Experts Tell FDA Not To Expect Too Much From Drug Ads On Web |
| 1:06 PM | 11/5/2009 | Amgen's Vectibix Misses Survival Goal,But Sales Could Benefit |
| 11/20/2009 | A month into an acquisition, and Merck already sees a benefit. |
| 11/20/2009 | Simplify your strategy. |
| 11/20/2009 | Health Fraud Caseload Grows |
| 11/19/2009 | For Lilly's R&D Chief, a $2 Million Exit Handshake |
| 11/18/2009 | It won't be a tough decision for patients to make. |
| 11/18/2009 | A new erectile-dysfunction drug shows promise. |
| 11/18/2009 | Take a closer look at the insider action at MannKind. |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.20 | 1.04 | 15.38 |
| EPS, GAAP | 0.86 | -0.43 | NA |
| Consensus Estimate | 1.02 | 1.01 | 0.99 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 4.59 | 4.02 | 14.18 |
| EPS, GAAP | -0.19 | 2.20 | NA |
| Consensus Estimate | 4.08 | NA | NA |
| LLY | Industry Average | |
| P/E (TTM) | -192.58 | 16.90 |
| P/E (Forward) | 8.28 | 1.10 |
| PEG Ratio | 2.37 | 0.07 |
| Price/Sales | 1.90 | 3.05 |
| Beta | 0.78 | 0.83 |